TABLE 2.
Baseline dog demographic and clinical characteristics.
| Variable | CHOP‐19 (155 dogs) | CHOP‐25 (347 dogs) | P‐value |
|---|---|---|---|
| Sex | .14 | ||
| Female entire | 6 (3.9%) | 28 (8.1%) | |
| Female neutered | 62 (40%) | 139 (40.1%) | |
| Male entire | 22 (14.2%) | 62 (17.9%) | |
| Male neutered | 65 (41.9%) | 118 (34%) | |
| Body weight (kg) | .98 | ||
| Median (range) | 22.5 (3.6‐66) | 22.7 (2.1‐86) | |
| Age (years) | .72 | ||
| Median (range) | 8 (1.1‐16) | 8.3 (1.5‐15.4) | |
| Breed distribution | .81 | ||
| Crossbreed | 39 (25.2%) | 87 (25.1%) | |
| Border Collie | 5 (3.2%) | 25 (7.2%) | |
| Cocker spaniel | 6 (3.9%) | 14 (4%) | |
| German shepherd | 6 (3.9%) | 12 (3.5%) | |
| Golden retriever | 11 (7.1%) | 18 (5.2%) | |
| Jack Russell terrier | 5 (3.2%) | 11 (3.2%) | |
| Labrador retriever | 8 (5.2%) | 20 (5.8%) | |
| Other | 75 (48.4%) | 160 (46.1%) | |
| Minimum stage | .75 | ||
| 3 | 78 (50.3%) | 182 (52.4%) | |
| 4 | 43 (27.7%) | 99 (28.5%) | |
| 5 | 34 (21.9%) | 66 (19%) | |
| Extranodal involvement | .61 | ||
| No | 133 (85.8%) | 305 (87.9%) | |
| Yes | 22 (14.2%) | 42 (12.1%) | |
| Substage | .12 | ||
| a | 97 (62.6%) | 190 (54.8%) | |
| b | 58 (37.4%) | 157 (45.2%) | |
| Presence of B‐symptoms | .43 | ||
| No | 101 (65.2%) | 240 (69.2%) | |
| Yes | 54 (34.8%) | 107 (30.8%) | |
| Pretreatment with corticosteroids (<14 days) | .99 | ||
| No | 133 (85.8%) | 296 (85.3%) | |
| Yes | 22 (14.2%) | 51 (14.7%) | |
| Presence of anemia | .9 | ||
| No | 103 (71%) | 241 (72.2%) | |
| Yes | 42 (29%) | 93 (27.8%) | |
| Presence of hypercalcemia | .25 | ||
| No | 135 (97.1%) | 317 (99.1%) | |
| Yes | 4 (2.9%) | 3 (0.9%) | |
| Institution | .002* | ||
| Academic | 63 (40.6%) | 92 (26.5%) | |
| Private | 92 (59.4%) | 255 (73.5%) | |
| Country | .01* | ||
| Non‐UK | 34 (21.9%) | 117 (33.7%) | |
| UK | 121 (78.1%) | 230 (66.3%) |
*
Significant differences (P < .05).
Abbreviation: CHOP, C = cyclophosphamide, H = hydroxydaunorubicin (Doxorubicin), O = Oncovin, P = prednisolone.